Thermo Fisher Scientific (TMO) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Key takeaways and strategic focus

• Achieved differentiated performance and strong market positioning, with continued market share gains in pharma, biotech, diagnostics, academia, and industrial applications.

• Long-term growth drivers include demographic shifts, scientific advances, AI-enabled drug discovery, and increased healthcare demand, especially in biologics and advanced modalities.

• Operational excellence is driven by the Practical Process Improvement (PPI) Business System, fostering a culture of continuous improvement and driving productivity, quality, and customer allegiance among 120,000 employees.

• Corporate social responsibility initiatives focus on societal impact, health equity, STEM education, and environmental sustainability, with significant progress in emissions reduction and renewable energy use.

• Financial performance is supported by a proven growth strategy, disciplined capital deployment, and a strong leadership team, with a 10% revenue CAGR, 12% adjusted EPS CAGR, and 11% free cash flow CAGR from 2014–2024.

2024 performance highlights and innovation

• Outperformed peers with faster growth despite a flat guidance year, gaining market share in a declining market.

• Major product launches and strong adoption in analytical instruments, proteomics, precision medicine, and advanced materials.

• Advanced trusted partner status through collaborations, new service launches, and global facility investments, including Accelerated Drug Development.

• AI adoption accelerated, with over half of employees using generative AI to enhance productivity, customer support, and internal operations.

• PPI-driven improvements led to double-digit reductions in inventory, lead times, and deviations, plus increased capacity at key sites.

Market outlook and growth strategy

• Served market estimated at $235B with a 20% share and $42.4B revenue; long-term market growth expected at 4%-6%.

• Short-term and long-term financial outlooks remain strong, with expectations to return to growth in Q4 2024 and build momentum into 2025.

• Pipeline of new products set to launch in 2024, supporting future growth.

• Confidence in maintaining 200-300 basis points of market share gain annually, supported by customer value creation and a flywheel effect.

• 2025 goals include continued share gains, innovation, trusted partner advancement, and further PPI-driven performance.